Tavistock
  • About
  • Team
  • Advice
  • Sectors
  • Case Studies
  • News
  • Get in touch

+44 (0) 20 7920 3150

Location

Cannongate House
62-64 Cannon Street
London, EC4N 6AE

Tavistock
  • About
  • Team
  • Advice
  • Sectors
  • Case Studies
  • News
  • Get in touch
Home  -   IPO: MGC Pharma

IPO: MGC Pharma

Tavistock MGC Pharma case study

IPO: MGC Pharma

Tavistock MGC Pharma case study

Company

MGC Pharma

Category

Consumer

Service

Corporate public relations

In February 2021 Tavistock helped make history as PR advisor to MGC Pharmaceuticals, the first medicinal cannabis company to IPO on the London Stock Exchange, which raised £6.5m in the process.

MGC Pharma is a European based bio-pharma company developing and supplying affordable standardised phyto-medicines to patients globally. It’s research and treatments are focused on using phytomedicines in three core areas: Neurology, Oncology, and Autoimmune diseases – including ArtemiC™ for treatment of Covid-19 infected patients.

Previous

Dual Listing: Resolute Mining

Next

IPO: Ten Lifestyle

A leading London-based corporate and financial communications consultancy.

Quick links

  • Home
  • Team
  • Advice
  • Sectors
  • News
  • Get in touch

+44 (0) 20 7920 3150

Location

Cannongate House
62-64 Cannon Street
London, EC4N 6AE

© 2026 Tavistock Communications Limited. All rights reserved. Registered in England and Wales No 2623799.